Synopsis Clinical evidence suggests that Degludec is a safe and effective long-acting basal insulin that can be used in a pediatric population with type 1 diabetes mellitus (T1DM). The present study aims to evaluate the efficacy and safety of Degludec as basal-bolus therapy in pediatric patients affected by T1DM. This week’s “ MED FACT ” discusses a clinical study from International Journal of Pediatric Endocrinology, “ Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population ”.27 July 2018. Authors : Inderpal Singh Kochar; Aashish Sethi.
Key Takeaways: Degludec therapy significantly reduces hypoglycemic episodes, bolus insulin doses and reduce nocturnal hypoglycemic episodes. Objective: To evaluate the efficacy and safety of Degludec in pediatric patients with T1DM. Study Type: Non-randomized, open-label…
